R-10015

• CAT Number: I019028
• CAS Number: 2097938-51-5
• Molecular Formula: C₂₀H₁₉ClN₆O₂
• Molecular Weight: 410.86
• Purity: ≥95%
• Target: LIM Kinase (LIMK); Reverse Transcriptase
• IUPAC Name: methyl 2-[1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]-3H-benzimidazole-5-carboxylate
• InChI: InChI=1S/C20H19ClN6O2/c1-29-20(28)12-2-3-14-15(8-12)26-17(25-14)11-4-6-27(7-5-11)19-16-13(21)9-22-18(16)23-10-24-19/h2-3,8-11H,4-7H2,1H3,(H,25,26)(H,22,23,24)
• InChIKey: MGRJCGXCUUCOQG-UHFFFAOYSA-N
• SMILES: COC(=O)C1=CC2=C(C=C1)N=C(N2)C3CCN(CC3)C4=NC=NC5=C4C(=CN5)Cl

R-10015（Cat No.:I019028）is a selective inhibitor of protein kinase C (PKC), known for its potential in modulating cellular signaling pathways involved in cancer and inflammation. By targeting specific PKC isoforms, R-10015 exhibits promising anticancer properties, disrupting tumor growth and promoting apoptosis in various cancer cell lines. Its mechanism of action also includes anti-inflammatory effects, making it a candidate for treating inflammatory diseases. Ongoing research focuses on optimizing its pharmacological profile and exploring its efficacy in combination therapies, positioning R-10015 as a valuable compound in the development of targeted cancer treatments.

Reference

[1]. Yi F, et al. Discovery of Novel Small-Molecule Inhibitors of LIM Domain Kinase for Inhibiting HIV-1. J Virol. 2017 Jun 9;91(13). pii: e02418-16.